These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36070138)

  • 1. Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer.
    Koshiro N; Nakajima K; Oyama M; Kaneko G; Takahashi S; Matsuyama H; Shiina H; Ichikawa T; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Mizokami A;
    Int J Urol; 2022 Dec; 29(12):1477-1487. PubMed ID: 36070138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
    Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
    Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
    Kamijima T; Yaegashi H; Mizokami A; Nakajima K; Matsuyama H; Ichikawa T; Nishimoto K; Takahashi S; Shiina H; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Enokida H
    Anticancer Res; 2022 Jun; 42(6):3099-3108. PubMed ID: 35641302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasic Prostate Cancer: Predictive Factors of Earlier Progression to Castration-Resistance.
    Dellavedova T; Malizia E; Quinteros L; Nobile R; Minuzzi F
    Arch Esp Urol; 2022 Jun; 75(5):430-434. PubMed ID: 35983814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
    Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
    Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.
    Nadal R; Tsai HL; Sinibaldi VJ; Paller CJ; Antonarakis ES; Denmeade SR; Carducci MA; Eisenberger MA
    Prostate; 2016 Apr; 76(5):512-20. PubMed ID: 26689606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
    Park K; Kim JY; Park I; Shin SH; Lee HJ; Lee JL
    Yonsei Med J; 2023 Feb; 64(2):86-93. PubMed ID: 36719015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
    Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
    Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
    Huang FM; Li XH; Liang Y
    Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer.
    Nakanishi S; Goya M; Tamaki M; Oshiro T; Saito S
    BMC Res Notes; 2021 Jun; 14(1):227. PubMed ID: 34082809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
    Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
    Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
    Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.
    Kawahara T; Yoneyama S; Ohno Y; Iizuka J; Hashimoto Y; Tsumura H; Tabata KI; Nakagami Y; Tanabe K; Iwamura M; Uemura H; Miyoshi Y
    Biomed Res Int; 2020; 2020():7804932. PubMed ID: 32714984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.